Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice

DMM Disease Models and Mechanisms

Volumn 5, Issue 3, 2012, Pages 397-402

  Lee, Chang Lung ^a   Moding, Everett J ^a   Huang, Xiaofang ^a   Li, Yifan ^a   Woodlief, Loretta Z ^a   Rodrigues, Rafaela C ^a   Ma, Yan ^a   Kirsch, David G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN P53; RECOMBINASE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CARCINOGENESIS; CONTROLLED STUDY; EXON; FIBROBLAST; FLIPPASE RECOGNITION TARGET; GENE DELETION; GENE TARGETING; GENETIC PARAMETERS; GENOTOXICITY; IN VITRO STUDY; LUNG CANCER; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SARCOMA;

ANIMALS; ATTACHMENT SITES, MICROBIOLOGICAL; CELL TRANSFORMATION, NEOPLASTIC; DNA NUCLEOTIDYLTRANSFERASES; EMBRYO, MAMMALIAN; FIBROBLASTS; GENE TARGETING; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE; MUS;

EID: 84860768426     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.009084     Document Type: Article

References (28)

1. Attardi, L. D., de Vries, A. and Jacks, T. (2004). Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene 23, 973-980. (Pubitemid 38250943)
2. Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Kenzelmann Broz, D., Basak, S., Park, E. J., McLaughlin, M. E. et al. (2011). Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145, 571-583.
3. Branda, C. S. and Dymecki, S. M. (2004). Talking about a revolution: the impact of site-specific recombinases on genetic analyses in mice. Dev. Cell 6, 7-28. (Pubitemid 38089202)
4. Brosh, R. and Rotter, V. (2009). When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 9, 701-713.
5. Donehower, L. A. and Lozano, G. (2009). 20 years studying p53 functions in genetically engineered mice. Nat. Rev. Cancer 9, 831-841.
6. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr, Butel, J. S. and Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221.
7. DuPage, M., Dooley, A. L. and Jacks, T. (2009). Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064-1072.
8. Graves, E. E., Vilalta, M., Cecic, I. K., Erler, J. T., Tran, P. T., Felsher, D., Sayles, L., Sweet-Cordero, A., Le, Q. T. and Giaccia, A. J. (2010). Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin. Cancer Res. 16, 4843-4852.
9. Hanahan, D. and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
10. Harvey, M., Sands, A. T., Weiss, R. S., Hegi, M. E., Wiseman, R. W., Pantazis, P., Giovanella, B. C., Tainsky, M. A., Bradley, A. and Donehower, L. A. (1993). In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8, 2457-2467. (Pubitemid 23252375)
11. Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T. and Weinberg, R. A. (1994). Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7.
12. Jackson, E. L., Olive, K. P., Tuveson, D. A., Bronson, R., Crowley, D., Brown, M. and Jacks, T. (2005). The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280-10288. (Pubitemid 41743720)
13. Kirsch, D. G., Dinulescu, D. M., Miller, J. B., Grimm, J., Santiago, P. M., Young, N. P., Nielsen, G. P., Quade, B. J., Chaber, C. J., Schultz, C. P. et al. (2007). A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat. Med. 13, 992-997. (Pubitemid 47222037)
14. Kirsch, D. G., Grimm, J., Guimaraes, A. R., Wojtkiewicz, G. R., Perez, B. A., Santiago, P. M., Anthony, N. K., Forbes, T., Doppke, K., Weissleder, R. et al. (2010). Imaging primary lung cancers in mice to study radiation biology. Int. J. Radiat. Oncol. Biol. Phys. 76, 973-977.
15. Lin, S. C., Lee, K. F., Nikitin, A. Y., Hilsenbeck, S. G., Cardiff, R. D., Li, A., Kang, K. W., Frank, S. A., Lee, W. H. and Lee, E. Y. (2004). Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res. 64, 3525-3532. (Pubitemid 38657927)
16. Maity, A. and Koumenis, C. (2010). Location, location, location-makes all the difference for hypoxia in lung tumors. Clin. Cancer Res. 16, 4685-4687.
17. Marino, S., Vooijs, M., van Der Gulden, H., Jonkers, J. and Berns, A. (2000). Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 14, 994-1004. (Pubitemid 30253007)
18. Martinez-Cruz, A. B., Santos, M., Lara, M. F., Segrelles, C., Ruiz, S., Moral, M., Lorz, C., Garcia-Escudero, R. and Paramio, J. M. (2008). Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res. 68, 683-692. (Pubitemid 351206743)
19. Meyers, E. N., Lewandoski, M. and Martin, G. R. (1998). An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination. Nat. Genet. 18, 136-141. (Pubitemid 28082459)
20. Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D. et al. (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461.
21. Oliver, T. G., Mercer, K. L., Sayles, L. C., Burke, J. R., Mendus, D., Lovejoy, K. S., Cheng, M. H., Subramanian, A., Mu, D., Powers, S. et al. (2010). Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 24, 837-852.
22. Raymond, C. S. and Soriano, P. (2007). High-efficiency FLP and PhiC31 site-specific recombination in mammalian cells. PLoS ONE 2, e162.
23. Sharpless, N. E. and Depinho, R. A. (2006). The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5, 741-754. (Pubitemid 44323701)
24. Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Bou Reslan, H., Ho, C. C. et al. (2010). Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 28, 585-593.
25. Stiewe, T. (2007). The p53 family in differentiation and tumorigenesis. Nat. Rev. Cancer 7, 165-168.
26. Tallquist, M. D. and Soriano, P. (2000). Epiblast-restricted Cre expression in MORE mice: a tool to distinguish embryonic vs. extra-embryonic gene function. Genesis 26, 113-115. (Pubitemid 30158091)
27. Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C. et al. (2002). p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45-53. (Pubitemid 34062443)
28. Young, N. P., Crowley, D. and Jacks, T. (2011). Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res. 71, 4040-4047.